Highlights
•DSM reports another strong quarter
•Group sales up at €1,998m, with 3% organic growth, and EBITDA up 13% to €323m
•Nutrition: 5% organic sales growth, EBITDA up 8%
•Materials: 5% volume growth, EBITDA up 16%
•Group ROCE improved to 10.6% (end Q3 2015: 7.9%) driven by higher EBIT
•Net profit up 38% to €146m (€322m after exceptionals, including proceeds from Patheon IPO)
•Outlook maintained

Key figures and indicators (continuing operations) .
in € million Q3 2016 Q3 2015 % change volume price/ mix FX other

Sales 1,998 1,945 3% 3% 0% 0% 0%
Nutrition 1,303 1,253 4% 3% 2% -1% 0%

Materials 634 631 0% 5% -5% -1% 1%
EBITDA 323 287 13%
Nutrition 231 213 8%
Materials 118 102 16%
ROCE (%)1 10.6 7.9
.

1) January until September

CEO statement
Feike Sijbesma, CEO/Chairman of the DSM Managing Board, commented: “We are pleased to report another quarter of strong operational and financial progress. This was driven by both Materials and Nutrition, reflecting the progress we are making on delivering on our Strategy 2018 through our growth initiatives as well as ambitious improvement and cost savings actions.

Materials had a quarter of strong volume growth driven again by specialties, enhanced by particularly high margins as a result of a very favorable product mix and pro-active margin management, while still benefiting from low input costs. Nutrition delivered good EBITDA growth, despite additional costs in the quarter. Animal Nutrition benefited from increased vitamin prices, with solid volume growth against a tougher prior year comparison. Human Nutrition delivered strong volume growth.

While the global macro-economic environment remains a concern, we continue to expect that for the full year 2016, we will deliver ahead of our medium-term goals, given the strong ongoing performance of our business, underpinned by our continued focus on the improvement programs.”

Outlook 2016 maintained

DSM continues to expect to deliver full-year 2016 results ahead of the medium-term targets set out in its Strategy 2018, with a mid-teens EBITDA growth and an increase in ROCE of over 200 basis points.

see and read more on
http://www.dsm.com/content/dam/dsm/cworld/en_US/documents/40-16-dsm-q3-2016-results.pdf

tijd 09.18
DSM EUR 56,75 - 39ct vol. 96.000